U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07327983) titled 'Azelaic Acid 20% vs Hydroquinone 4% in Epidermal Melasma' on Dec. 25, 2025.
Brief Summary: Melasma is a common skin condition that causes dark patches on the face and can significantly affect quality of life. This study compared two commonly used topical treatments, 20% azelaic acid and 4% hydroquinone, in adults with epidermal melasma.
Participants with epidermal melasma were randomly assigned to receive either azelaic acid 20% or hydroquinone 4% for a period of 12 weeks. The severity of melasma was assessed at baseline and monthly using the Melasma Area and Severity Index (MASI) score. Side effects such as irritation, redness, bur...